Sichuan Kelun Pharmaceutical
Sichuan Kelun Pharmaceutical Co Ltd is a Chinese pharmaceutical manufacturer producing intravenous (IV) infusions, prescription generic medicines, active pharmaceutical ingredients (APIs), and novel antibody-drug conjugates (ADCs) globally. The company manufactures large-volume IV parenteral solutions, antibiotics, oncology drugs, and advances innovative ADC oncology therapeutics via its R&D platform Kelun-Biotech in partnership with AstraZeneca and Merck. Principal revenues derive from direct product sales of IV infusions and prescription drugs to hospital networks, clinics, and pharmaceutical distributors alongside strategic R&D licensing fees. Core end markets encompass public hospital systems, clinical medical centers, retail pharmacies, and prescription patients in China, North America, and Europe. Sichuan Kelun Pharmaceutical holds the dominant market leadership position in China for large-volume intravenous fluid manufacturing. The company is headquartered in Chengdu, China, and its common shares trade on the Shenzhen Stock Exchange.
2 of the funds FundTelligence covers report a position in Sichuan Kelun Pharmaceutical.
- Legal name
- SICHUAN KELUN PHARMACEUTICAL LTD
- Sector
- Health Care
- Country
- China
- Funds holding it
- 2
Funds holding Sichuan Kelun Pharmaceutical
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- KLP AksjeFremvoksende Markeder Indeks — KLP · 0.0 % (full portfolio disclosed, June 2026)